Page last updated: 2024-12-07

bd 1008

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BD 1008: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126388
CHEMBL ID20377
CHEBI ID92304
SCHEMBL ID678162
MeSH IDM0226946

Synonyms (29)

Synonym
dempea
BRD-K17008822-303-01-3
NCGC00024625-01
tocris-0511
NCGC00024625-02
bd-1008
CHEMBL20377 ,
2-(3,4-dichlorophenyl)-n-methyl-n-(2-pyrrolidin-1-ylethyl)ethanamine
[2-(3,4-dichloro-phenyl)-ethyl]-methyl-(2-pyrrolidin-1-yl-ethyl)-amine
bdbm50000069
bd1008 ,
138356-08-8
n-(2-(3,4-dichlorophenyl)ethyl)-n-methyl-2-(1-pyrrolidinyl)ethylamine
bd 1008
jcy43qe7fq ,
n-(2-(3,4-dichlorophenyl)ethyl)-n-methyl-1-pyrrolidineethanamine
unii-jcy43qe7fq
1-pyrrolidineethanamine, n-(2-(3,4-dichlorophenyl)ethyl)-n-methyl-
SCHEMBL678162
DTXSID60160639
CHEBI:92304
J-007121
n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-(1-pyrrolidinyl)ethylamine
2-(3,4-dichlorophenyl)-n-methyl-n-[2-(1-pyrrolidinyl)ethyl]ethanamine
Q12744660
HMS3742M03
1-pyrrolidineethanamine, n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-
n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-1-pyrrolidineethanamine
bd1008-d5dihydrobromide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Lu 28-179 and BD 1008 potentiated dose-dependently the NMDA response and generated bell-shaped dose-response curves."( Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands.
Couture, S; Debonnel, G, 1998
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary amineA compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency31.62280.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency63.09570.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency11.96720.000811.382244.6684AID686978; AID686979
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926
67.9K proteinVaccinia virusPotency20.38650.00018.4406100.0000AID720579; AID720580
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.79430.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.11890.316212.443531.6228AID902
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID881
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vitamin D-binding proteinRattus norvegicus (Norway rat)Ki0.00210.00210.00290.0037AID229212
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki1.11200.00000.437510.0000AID64954
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.00140.00000.490110.0000AID203683; AID204460; AID204766; AID229194; AID229195; AID229212
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID204460Binding affinity against [3H]-3-PPP labelled sigma sites1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Structural features important for sigma 1 receptor binding.
AID232239Selectivity and expressed as ratio of sigma 2/sigma 12000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays.
AID229195Binding affinity against sigma receptor from guinea pig brain, using [3H](+)-3-PPP as radioligand.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents.
AID64954Binding affinity against Dopamine receptor D2 from rat brain, using [3H](-)-sulpiride as radioligand.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents.
AID203697Binding affinity towards sigma 1 receptor was determined in guinea pig brain membrane using [3H](+)-pentazocine as radioligand1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID229212Binding affinity was evaluated against sigma-1 binding site in guinea pig, using [3H]- -(+)- Pentazocine1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and binding characteristics of potential SPECT imaging agents for sigma-1 and sigma-2 binding sites.
AID229194Displacement of [3H]-(+) -3PPP from sigma receptor in guinea pig brain membranes1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor.
AID149116Binding affinity against Opioid receptor kappa 1 from guinea pig brain, using [3H](-)-bremazocine as radioligand; NI=no inhibition1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents.
AID229217Binding affinity was evaluated against sigma-2 binding site in rat liver using [3H]DTG -(+)-Dextrallorphan as radioligand1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and binding characteristics of potential SPECT imaging agents for sigma-1 and sigma-2 binding sites.
AID64927Ability to displace [3H]sulpiride from dopamine receptor D2 in rat brain1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor.
AID204766Binding affinity towards Sigma-1 receptor2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
1,4-dibenzylpiperazines possess anticocaine activity.
AID231161Ratio of the sigma-2 receptor versus sigma-1 receptor1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and binding characteristics of potential SPECT imaging agents for sigma-1 and sigma-2 binding sites.
AID203827Binding affinity against sigma 2 opioid receptor using 3[H]-DTG in the presence of dextrallorphan as radioligand2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays.
AID203842Binding affinity towards sigma 2 receptor was determined in rat liver membrane using [3H]DTG as radioligand in presence of dextrallorphan1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID156822Ability to displace [3H]TCP from PCP receptor in guinea pig membranes; No inhibition1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor.
AID203683Compound was tested for its binding affinity against sigma 1 opioid receptor using 3[H](+)-pentazocine as radioligand2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID147972Ability to displace [3H]bremazocine from opioid receptor kappa in guinea pig brain membranes; No inhibition1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor.
AID157445Binding affinity against phencyclidine (PCP) receptor from guinea pig brain, using [3H]-TCP as radioligand; NI=no inhibition1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and receptor binding properties of fluoro- and iodo-substituted high affinity sigma receptor ligands: identification of potential PET and SPECT sigma receptor imaging agents.
AID203691Inhibition Constant for 4-[125I]-IPBS binding to sigma 1 receptor in guinea pig brain membranes1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents.
AID203851Relative binding to sigma-2 and sigma-1 type receptors, ratio of Ki1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID203820Tested for its binding affinity towards sigma-1 site in rat brain, using [3H](+)-3-PPP as radioligand1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands.
AID229218The Binding affinity was evaluated against sigma-2 binding site in rat liver using [3H]- -(+)-3-PPP1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and binding characteristics of potential SPECT imaging agents for sigma-1 and sigma-2 binding sites.
AID204443Ability to displace [3H](+)-pentazocine at sigma receptor in guinea pig brain membrane was determined1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds.
AID204445Binding affinity for sigma receptor using [3H](+)-pentazocine in guinea pig brain homogenates1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes.
AID204786Binding affinity towards Sigma-2 receptor2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
1,4-dibenzylpiperazines possess anticocaine activity.
AID125755Anticocaine activity was assessed through attenuation of convulsions caused by the intraperitoneal administration of cocaine 60 mg/kg in mice2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
1,4-dibenzylpiperazines possess anticocaine activity.
AID493017Wombat Data for BeliefDocking1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (57.14)18.2507
2000's8 (28.57)29.6817
2010's1 (3.57)24.3611
2020's3 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.00 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]